| 2026-08-17 | Press release | Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees |
| 2026-08-11 | Press release | Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders |
| 2026-08-03 | Press release | Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Cr |
| 2026-07-30 | Press release | Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-22 | Press release | Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification |
| 2026-05-06 | Press release | Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, |
| 2026-04-14 | Press release | Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease |
| 2026-04-07 | Press release | Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-30 | Press release | Anavex Life Sciences Provides Comprehensive Regulatory Update |
| 2026-03-25 | Press release | Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease |
| 2026-03-23 | Press release | Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consis |
| 2026-03-21 | Presentation | Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine with Long-term Time Saved |
| 2026-03-20 | Press release | New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Al |
| 2026-03-17 | Press release | Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Par |
| 2026-03-03 | Press release | Anavex Life Sciences to Present at the Citizens Life Sciences Conference |
| 2026-02-25 | Press release | Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference |
| 2026-02-23 | Press release | Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors |
| 2026-02-09 | Press release | Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update |
| 2026-02-03 | Press release | Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 |
| 2026-01-13 | Press release | Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcam |
| 2026-01-08 | Press release | Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology |
| 2026-01-06 | Press release | Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program |
| 2025-12-18 | Press release | Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion |
| 2025-12-12 | Press release | Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease |
| 2025-12-02 | Presentation | CTAD Marwan Sabbagh, MD Oral Presentation 2025 |
| 2025-11-26 | Press release | Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Confere |
| 2025-11-25 | Press release | Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update |
| 2025-11-19 | Press release | Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference |
| 2025-11-18 | Press release | Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 |
| 2025-11-14 | Press release | Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease |
| 2025-10-29 | Press release | Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Al |
| 2025-10-10 | Press release | Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: |
| 2025-10-06 | Presentation | Alzheimer Europe October 2025 Presentation |
| 2025-10-02 | Press release | Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program |
| 2025-10-02 | Press release | Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophr |
| 2025-09-30 | Press release | Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine fr |
| 2025-09-29 | Presentation | RFMASA Conference 2025 Poster |
| 2025-09-09 | Press release | Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precisio |
| 2025-08-20 | Press release | Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism |
| 2025-08-20 | Press release | Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal |